Evolus (NASDAQ:EOLS)‘s stock had its “buy” rating restated by Cantor Fitzgerald in a research note issued on Monday. They currently have a $35.00 price target on the stock. Cantor Fitzgerald’s target price suggests a potential upside of 86.12% from the company’s previous close.

The analysts wrote, “Based on our due diligence, dermatologists and plastic surgeons appreciate the value proposition of Evolus’s botulinum toxin as a nearly identical product to market-leader Botox sold at a discount. Therefore, we think DWP-450 could pick up meaningful market share if it is approved. and other potential upcoming catalysts should drive EOLS shares higher. Valuation Summary We use a blend of EV/EBITDA and DCF analysis to arrive at our $35 12-month price target.””

Several other equities research analysts have also issued reports on EOLS. ValuEngine raised shares of Evolus from a “hold” rating to a “buy” rating in a report on Monday, July 2nd. JMP Securities upped their target price on shares of Evolus from $22.00 to $30.00 and gave the stock an “outperform” rating in a report on Tuesday, May 29th. Mizuho upped their target price on shares of Evolus from $16.00 to $33.00 and gave the stock a “buy” rating in a report on Monday, June 11th. Zacks Investment Research raised shares of Evolus from a “hold” rating to a “buy” rating and set a $28.00 target price on the stock in a report on Tuesday, July 17th. Finally, SunTrust Banks reaffirmed a “buy” rating and issued a $27.00 target price on shares of Evolus in a report on Monday, August 6th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Evolus has a consensus rating of “Buy” and a consensus target price of $30.40.

Evolus stock traded up $0.11 on Monday, hitting $18.81. The company’s stock had a trading volume of 69,191 shares, compared to its average volume of 367,056. The firm has a market capitalization of $564.71 million and a PE ratio of -69.65. Evolus has a one year low of $6.75 and a one year high of $39.50.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings results on Thursday, August 2nd. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.05). sell-side analysts forecast that Evolus will post -1.9 EPS for the current year.

In related news, Director Kristine Romine acquired 10,000 shares of the firm’s stock in a transaction on Wednesday, August 22nd. The shares were purchased at an average price of $19.83 per share, with a total value of $198,300.00. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Corp Alphaeon sold 1,000,000 shares of the stock in a transaction dated Monday, July 23rd. The stock was sold at an average price of $18.80, for a total transaction of $18,800,000.00. The disclosure for this sale can be found here.

Large investors have recently modified their holdings of the business. SG Americas Securities LLC bought a new stake in Evolus during the 2nd quarter worth about $108,000. Tower Research Capital LLC TRC grew its holdings in Evolus by 761.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,555 shares of the company’s stock worth $183,000 after acquiring an additional 5,794 shares during the last quarter. Schwab Charles Investment Management Inc. bought a new stake in Evolus during the 2nd quarter worth about $258,000. Alpine Woods Capital Investors LLC bought a new stake in Evolus during the 2nd quarter worth about $280,000. Finally, Raymond James Financial Services Advisors Inc. bought a new stake in Evolus during the 2nd quarter worth about $303,000. 13.20% of the stock is currently owned by hedge funds and other institutional investors.

About Evolus

Evolus, Inc provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.

See Also: Technical Analysis of Stocks and What It Means

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.